Cargando…
A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant t...
Autores principales: | Simonenko, Vera, Lu, Xiaoyong, Roesch, Eric, Mutisya, Daniel, Shao, Chunbo, Sun, Qian, Patterson-Orazem, Athéna, McNair, Marcus, Shanmuganathan, Aranganathan, Lu, Patrick, Evans, David M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209983/ https://www.ncbi.nlm.nih.gov/pubmed/34316688 http://dx.doi.org/10.1093/narcan/zcaa016 |
Ejemplares similares
-
The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020) -
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
por: Sule, Amrita, et al.
Publicado: (2021) -
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice
por: Müller, Simon, et al.
Publicado: (2020) -
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses
por: Núñez-Manchón, Estela, et al.
Publicado: (2021) -
Targeted zinc-finger repressors to the oncogenic HBZ gene inhibit adult T-cell leukemia (ATL) proliferation
por: Scott, Tristan A, et al.
Publicado: (2023)